Novel Alzheimer's disease brain function evaluation method

Abstract

The invention discloses a novel Alzheimer's disease brain function evaluation method. The method comprises the following steps that brain function activity data of a patient are collected for brain blood oxygen saturation analysis, and neural activities of the brain of the patient are monitored and recorded in real time when a cognitive task is executed through the fNIRS technology. Brain function activity data are analyzed to obtain brain blood oxygen saturation parameters, fNIRS data are processed and analyzed, and characteristic indexes related to the Alzheimer's disease are extracted, such as abnormity of a brain activation area, change of functional connection and the like. An Alzheimer's disease blood oxygen saturation degree brain function evaluation model is established, and an evaluation model capable of accurately predicting and quantifying the severity of the Alzheimer's disease is established based on a large amount of clinical sample data. And the obtained brain function blood oxygen saturation degree data is input into the evaluation model, so that the cognitive function state can be objectively evaluated, and the development trend of the illness state can be predicted. And favorable evidence is provided for early diagnosis of the Alzheimer's disease.

Description

Technical Field

[0001] This invention relates to an evaluation method for the early diagnosis of Alzheimer's disease. Background Technology

[0002] Alzheimer's disease is one of the most common neurodegenerative diseases, with main symptoms including cognitive impairment, memory loss, and behavioral changes. Current diagnostic methods for Alzheimer's disease mainly rely on clinical symptom assessment and neuropsychological testing, but these methods have limited accuracy and cannot objectively quantify the progression of the disease. Summary of the Invention

[0003] To overcome the shortcomings of existing technologies, this invention proposes a novel brain function evaluation system for Alzheimer's disease, which can provide an effective means for the early diagnosis and monitoring of Alzheimer's disease by detecting changes in the patient's brain functional activity.

[0004] The technical problem to be solved by the present invention is achieved through the following technical solution: Firstly, a novel method for evaluating brain function in Alzheimer's disease is characterized by comprising the following steps: (1) Collect data on the patient's brain function activity. (2) Analyze brain functional activity data. (3) Establish a brain function evaluation model for Alzheimer's disease. (4) Conduct disease monitoring and prediction.

[0005] In this invention, step (1) specifically includes: using fNIRS technology to monitor and record the neural activity and blood oxygen saturation of the patient's brain in real time when performing cognitive tasks.

[0006] In this invention, step (2) specifically includes: processing and analyzing fNIRS data to extract characteristic indicators related to Alzheimer's disease, such as changes in brain blood oxygen saturation, abnormalities in activated areas, and changes in functional connectivity.

[0007] In this invention, step (3) specifically includes: establishing an evaluation model that can accurately predict and quantify the severity of Alzheimer's disease based on a large amount of clinical sample data.

[0008] In this invention, step (4) specifically includes: inputting the obtained brain function oxygen saturation data into the evaluation model, so as to objectively assess the cognitive function status and predict the development trend of the disease. Detailed Implementation

[0009] Unless otherwise specified, the raw materials and equipment used in this invention are all commonly used in the field; unless otherwise specified, the methods used in this invention are all conventional methods in the field.

[0010] Unless otherwise specified, the terms used in this specification have the same meaning as those commonly understood by those skilled in the art; however, in the event of any conflict, the definitions in this specification shall prevail.

[0011] The terms “comprising,” “including,” “containing,” “having,” “comprising,” or other variations thereof are intended to cover non-closed inclusion, and no distinction is made between these terms. The term “comprising” means that other steps and ingredients may be added without affecting the final result. The term “comprising” also includes the terms “consisting of” and “substantially consisting of”. The compositions and methods / processes of the present invention comprise, consist of, and substantially consist of the essential elements and limitations described herein, as well as any additional or optional ingredients, components, steps, or limitations described herein.

[0012] All numerical values ​​or expressions relating to component amounts, process conditions, etc., used in the specification and claims are to be understood to be modified with “about” in all cases. All ranges relating to the same component or property include endpoints that can be independently combined. Because these ranges are continuous, they include every value between the minimum and maximum values. It should also be understood that any numerical range referenced in this application is intended to include all subranges within that range.

[0013] The present invention will now be described in detail with reference to the embodiments. These embodiments are merely preferred implementations of the present invention and are not intended to limit the present invention.

[0014] Example 1

[0015] This embodiment provides a method for evaluating brain function in Alzheimer's disease. The cognitive task (Moca scale) is as follows: Each task lasts approximately 5-8 minutes and includes the processes of putting on a headgear, confirming patient information, equipment self-checking, and data collection. The task consists of three phases: preparation, task, and recovery. The preparation phase lasts 30 seconds, during which the user remains calm to achieve a relatively stable state. The task phase lasts 60 seconds, with a visual prompt appearing every 20 seconds. The recovery phase lasts 55 seconds, during which the task is discontinued to allow the user to return to a stable state. A typical operating procedure is as follows: (1) Check that all connections of the equipment are normal. This includes the external power cord, marking lines, etc. (2) Turn on the main power switch at the back of the chassis. If the green power indicator light on the switch is on, the power supply is normal. (3) Turn on the power switch at the front of the chassis. The power indicator light will illuminate, and the host will start running. At the same time, the communication indicator light will flash, indicating that the host and the data acquisition PC are communicating normally. (4) Turn on the data acquisition PC. (5) Double-click the data acquisition software OBS on the desktop. (6) Wear the head cap with the installed probe support buckle, and insert the fiber optic probe into the support buckle according to the SD configuration to test the signal quality. (7) Data acquisition begins, and the data acquisition indicator light flashes. (8) After data acquisition is complete, first turn off the data acquisition PC, then turn off the power switch at the front of the chassis, and finally turn off the main power switch at the rear of the chassis. The typical operation process of the data acquisition software OBS is as follows: (1) Open the OBS software. (2) Click the “File” menu and select “New Experiment” or “Load Experiment”. (3) Fill in the subject information. (4) Click “Probe Settings” and select “New” or “Load”. (5) Click "Static Test" or "Dynamic Test". (6) Click “Start”. (7) During the data collection process, you can click to switch between the various options in the display mode. (8) Click “Stop” after the data collection is complete.

[0016] Example 2 This example provides a method for evaluating brain function in Alzheimer's disease. The changes in the concentrations of oxygen, hemoglobin, deoxyhemoglobin, and total hemoglobin in the blood of the cerebral cortex are measured to obtain a curve of changes in human brain blood oxygen concentration, which can be used to assess brain function status.

[0017] The above embodiments merely illustrate the implementation of the present invention, and their descriptions are relatively specific and detailed. However, they should not be construed as limiting the scope of the present invention. Any technical solutions obtained by adopting equivalent substitutions or equivalent transformations should fall within the protection scope of the present invention.

Claims

1. A novel method for evaluating brain function in Alzheimer's disease, characterized by, It comprises the following steps: (1) Collecting patient brain function activity data. (2) Analyzing brain function activity data. (3) Establishing Alzheimer's brain function evaluation model. (4) Conducting disease monitoring and prediction.

2. The method of claim 1, wherein, The step (1) specifically includes: using fNIRS technology to monitor and record the patient's brain neural activity, blood oxygen saturation and other information when performing cognitive tasks in real time.

3. The preparation method according to claim 1, characterized in that, The step (2) specifically includes: processing and analyzing fNIRS data, extracting characteristic indicators related to Alzheimer's disease, such as changes in brain blood oxygen saturation, abnormal activation regions, changes in functional connectivity, etc.

4. The method of claim 1, wherein, The step (3) specifically includes: based on a large number of clinical sample data, establishing an evaluation model that can accurately predict and quantify the severity of Alzheimer's disease.

5. The preparation method according to claim 1, characterized in that, The step (4) specifically includes: inputting the obtained brain function blood oxygen saturation data into the evaluation model, which can objectively evaluate the cognitive function status and predict the development trend of the disease.

6. A novel method for evaluating brain function in Alzheimer's disease, characterized by, It is as claimed in any one of claims 1-5.

7. Use of the brain function evaluation method as claimed in claims 1-5 in Alzheimer's disease.